Shah Vinay 4
4 · Aravive, Inc. · Filed Oct 16, 2018
Insider Transaction Report
Form 4
Aravive, Inc.ARAV
Shah Vinay
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2018-10-12+19,380→ 19,380 totalExercise: $0.24Exp: 2024-09-30→ Common Stock (19,380 underlying) - Award
Stock Option (Right to Buy)
2018-10-12+19,000→ 19,000 totalExercise: $0.90Exp: 2027-12-14→ Common Stock (19,000 underlying) - Award
Stock Option (Right to Buy)
2018-10-12+38,001→ 38,001 totalExercise: $0.66Exp: 2027-06-15→ Common Stock (38,001 underlying) - Award
Stock Option (Right to Buy)
2018-10-12+19,000→ 19,000 totalExercise: $0.90Exp: 2028-03-20→ Common Stock (19,000 underlying) - Award
Common Stock
2018-10-12+178,606→ 178,606 total
Footnotes (5)
- [F1]Shares of common stock of the corporation known as Aravive Biologics, Inc. ("Aravive") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and among the Issuer, Velo Merger Sub, Inc. and Aravive (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of Aravive common stock was exchanged for 2.2801 shares of the Issuer's common stock, subject to adjustment for any reverse stock split. Following the merger, the Issuer effected a reverse stock split at a ratio of one new share for every six shares of Issuer common stock outstanding and the Issuer changed its name to Aravive, Inc. All share and option numbers reflect the reverse stock split.
- [F2]On October 1, 2014, Reporting Person was granted an option to purchase 51,000 shares of the common stock of Aravive at an exercise price of $0.09 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,380 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.24 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
- [F3]On June 15, 2017, Reporting Person was granted an option to purchase 100,000 shares of the common stock of Aravive at an exercise price of $0.23 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 38,001 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.66 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
- [F4]On December 14, 2017, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.
- [F5]On March 20, 2018, Reporting Person was granted an option to purchase 50,000 shares of the common stock of Aravive at an exercise price of $0.34 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 19,000 shares of Issuer common stock (as adjusted for the stock split) at a per share exercise price of $0.90 per share (as adjusted for the stock split). The option is fully vested with respect to all of the underlying shares and exercisable as of the effective date of the merger.